BSX · Full Picture

BOSTON SCIENTIFIC CORP — the full picture

Earnings window · 2026-08-03 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 98
    +16.0% assets; 4 sources (news, press_release, sec_filing, transcript); 9 forward row(s); structured_verified
    Boston Scientific announced on January 15, 2026 a definitive agreement to acquire 100% of Penumbra for $374 per share, or approximately $14.500 billion, with the transaction expected to be completed in the second half of 2026 subject to customary closing conditions including regulatory clearances.
  2. Liquidity and Cash Position · Liquidity & cash positionPriority 93
    -12.2% liability; 3 sources (news, sec_filing, transcript); 1 forward row(s); structured_verified
    On February 26, 2026, Boston Scientific entered into a $2.000 billion 364-day revolving credit agreement and a $6.000 billion term loan credit agreement that permit up to a $1.000 billion Tranche A Loan and up to a $5.000 billion Tranche B Loan, each drawable only upon closing of the pending Penumbra acquisition and maturing 364 days thereafter.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 78
    +30.9% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); structured_verified
    Boston Scientific reported Q2 EPS of $0.86 and revenue of $5.44 billion, alongside a 7.5% year-over-year revenue growth.
  4. Market Demand Trends · Demand, orders & backlogPriority 74
    4 sources (news, press_release, sec_filing, transcript); 3 forward row(s); quote_verified
    The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030.
  5. Restructuring and Cost Savings · Restructuring & impairmentPriority 74
    -4.1% operating_income; 2 sources (sec_filing, transcript); 3 forward row(s); structured_verified
    On July 21, 2026, the board approved and Boston Scientific committed to a new global restructuring plan expected to incur $700 million to $800 million of pretax charges, including $600 million to $700 million of future cash outlays, and reduce gross annual pretax expenses by approximately $500 million as benefits are realized.
  6. Income Tax Rate Changes · TaxPriority 72
    +7.1% net_income (realized); 3 sources (press_release, sec_filing, transcript); structured_verified
    Boston Scientific recorded a $383 million discrete tax benefit in the first nine months of 2026 to reflect a change in the anticipated future tax rate for recovery of certain capitalized expenses.
  7. Net Income and EPS Performance · Operating income & profitabilityPriority 72
    +13.6% net_income (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Nine-month 2026 reported net income attributable to Boston Scientific common stockholders was $2,830 million, up 27.1% year over year.
  8. Stock Repurchase Program · Buybacks & dividendsPriority 70
    -4.4% cash (realized); 2 sources (news, sec_filing); 1 forward row(s); structured_verified
    Boston Scientific announced an accelerated share repurchase program of $2.000 billion.
  9. Restructuring Charges · Restructuring & impairmentPriority 69
    -2.3% operating_income; 3 sources (news, press_release, sec_filing); 3 forward row(s); quote_verified
    Boston Scientific announced a new global restructuring plan expected to result in pre-tax charges of $700-800 million and annual pre-tax savings of $500 million.
  10. Gross Margin Drivers · Gross marginPriority 64
    +4.9% margin (realized); 3 sources (press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Gross profit for the second quarter of 2026: $3,848 million, compared to $3,424 million for the second quarter of 2025.
  11. Guidance / Outlook · Guidance & outlookPriority 63
    +1.9% revenue; 3 sources (news, press_release, transcript); 8 forward row(s); quote_verified
    Boston Scientific's updated 2026 guidance tempered sales growth expectations to 6.5%-8.0% organically, down from previous double-digit forecasts.
  12. Cybersecurity Incident Disruption · Cybersecurity & incidentsPriority 62
    -2.1% revenue; 3 sources (news, sec_filing, transcript); 7 forward row(s); quote_verified
    Boston Scientific no longer expects to meet its third-quarter 2026 sales and adjusted profit forecasts due to the cyberattack.

Threads by pillar

Revenue & Demand Priority 90 · 8 threads

Costs & Margins Priority 91 · 8 threads

Capital & Balance Sheet Priority 97 · 5 threads

Strategy & Portfolio Priority 98 · 2 threads

Legal, Regulatory & Policy Priority 57 · 6 threads

Guidance & Outlook Priority 63 · 1 thread

Macro & Market Conditions Priority 53 · 2 threads

Management & Governance Priority 65 · 3 threads

Unclassified Priority 78 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-6.4%+32.2%+4.3%
liability-24.4%+24.4%—
assets+16.0%+16.0%—
revenue+0.1%+7.7%+27.9%
cash-1.1%+1.3%-8.9%
margin——+5.7%
net_income——+20.6%